Safety of leflunomide and methotrexate as combination therapy for rheumatoid arthritis: a review of the clinical evidence
Canadian Agency for Drugs and Technologies in Health
Record ID 32011000940
English
Authors' recommendations:
The available evidence related to the safety of combination therapy with LEF and MTX in patients with RA is limited and inconclusive. There is some suggestion of increased risk of abnormal liver function with LEF and MTX combination therapy.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/htis/may-2011/RCO268_safety_of_leflunomide_and_methotrexate_Final.pdf
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Isoxazoles
- Methotrexate
- Arthritis, Rheumatoid
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.